ÂÜÀòÂÒÂ×

Drew Fromkin is the Vant Portfolio Operating Partner for Roivant Sciences and serves on the board of Immunovant (NASDAQ: IMVT) as chair of the compensation and nominating and governance committees. Mr. Fromkin has over 30 years of leadership experience in major areas of the healthcare industry, including the biopharmaceuticals, life sciences and healthcare services sectors. He has an accomplished track record leading public and private companies through all stages of development and value creation.

Mr. Fromkin previously served as the President, CEO and Chairman of Tarveda Therapeutics, Inc. where he restructured, capitalized and advanced the Company to a clinical-stage precision oncology company with a platform focused on targeted miniature conjugates for the treatment of patients with solid tumors. Prior to Tarveda, Mr. Fromkin served as President, CEO and Director of Clinical Data, Inc. (NASDAQ: CLDA) where he transformed the Company over five years from a traditional diagnostics business with approximately a $75 million market capitalization to an innovative biopharmaceutical and personalized medicine company. In 2011, CLDA was acquired by Forest Laboratories (FRX) for $1.5 billion. Prior to Clinical Data, Mr. Fromkin served as President and CEO of DoctorQuality, Inc. (acquired by Quantros, Inc.), President, CEO of Endo Surgical Devices, Inc., and Corporate Vice President, Business Development, for Merck-Medco, a wholly owned subsidiary of Merck & Co.

Mr. Fromkin also served as a director on the audit committee and chair of the compensation committee for Tobira Therapeutics, Inc. (TBRA), which was acquired for $1.7 billion by Allergan (AGN), and on the board of Xoc Pharmaceuticals. Mr. Fromkin holds a B.A. from Brandeis University.